Tomahawk, WI 08/29/2014 (Basicsmedia) – Plans to begin Safety trials on an Ebola Vaccine by NIH and GlaxoSmithKline plc (ADR) (NYSE:GSK) are reportedly underway according to CNBC’s Meg Tirrell. Healthy volunteers could be used for the trials as early as next month. The announcement is good news as this is the deadliest Ebola outbreak in the recent past, seen by 3,000 cases in West Africa with more than 1,500 deaths reported so far.
NIH and GlaxoSmithKline plc (ADR) (NYSE:GSK) will spearhead the vaccine trials. If successful by the end of the year, the vaccine could be given to infected people especially in West Africa.
“GlaxoSmithKline plc (ADR) (NYSE:GSK) actually saying they got a £2.8 million grant from the Welcome Trust and other organization in the U.K, which will enable it to actually build 10,000 additional doses of this vaccine which it says it will give to the WHO if the trials are positive,” said Mrs. Tirrell.
GlaxoSmithKline plc (ADR) (NYSE:GSK) is planning to produce an additional 10,000 doses for its vaccine so that if successful in the trial stage, it could be made readily available to infected patients.
Another vaccination could also be in the pipeline other than the one being produced by GlaxoSmithKline with NIH saying it will start trials for a compound, sometime in the fall. Most of the stocks in the Ebola portfolio were down in Thursday trading session attributed to news that GlaxoSmithKline plc (ADR) (NYSE:GSK) had taken the pole position with its Ebola trail vaccine. Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) on the other hand was up in the market as reports emerged that it could be a possible take out company.
GlaxoSmithKline opting to produce only 10,000 doses for its vaccine raises questions as to whether it will be successful in the trial stages, considering WHO is reporting that up to 20,000 people might have been infected by the deadly disease. Tirrell believes that 10,000 doses’ is still high as it will only be administered’ to high-risk patients.
“We would only want to vaccinate the really high-risk folks. 10,000 actually seems to me like kind of a lot, especially because they are talking doing it after they just potentially complete a phase one safety study,” said Mrs. Tirrell.